CCM
HOOK

CAAS Capital Management’s HOOKIPA Pharma HOOK Stock Holding History

CAAS Capital Management’s Portfolio HOOK Stock Details HOOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,123
Closed -$125K – 1266
2020
Q4 		$125K Buy
+1,123
New +$121K ﹤0.01% 784

Other funds holding HOOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

CAAS Capital Management's HOOK Position: Q1 2021 in Review

CAAS Capital Management sold out of HOOKIPA Pharma (HOOK) in Q1 2021, closing a stake of 1,123 shares — an estimated $125K sold.

CAAS Capital Management first reported a position in HOOK in Q4 2020 and held it in 1 quarter. The position peaked at $125K in Q4 2020. 62 funds tracked by Wall St. Rank hold HOOK as of Q1 2021.

  • CAAS Capital Management reported no remaining HOOKIPA Pharma position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 1,123 HOOKIPA Pharma shares in Q1 2021, an estimated $125K.
  • CAAS Capital Management first reported a position in HOOKIPA Pharma in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's HOOKIPA Pharma position peaked at $125K in Q4 2020.
  • 62 funds tracked by Wall St. Rank held HOOKIPA Pharma as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.